Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CGA-Guided Ultrafractionated RT and Sintilimab in Inoperable Colorectal Cancer
NCT06652412Phase 2Not yet recruiting
- Sponsor
- Fudan University
- Start
- Nov 2024
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies
01
Overview
Phase 2, open-label trial of sintilimab in colorectal cancer (CRC) (2 cohorts), sponsored by Fudan University. Primary endpoint: Complete Response Rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06652412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06652412.